Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,000
Employees17,000
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,000
Employees17,000

GILD Key Statistics

Market cap
167.59B
Market cap167.59B
Price-Earnings ratio
18.36
Price-Earnings ratio18.36
Dividend yield
2.36%
Dividend yield2.36%
Average volume
6.62M
Average volume6.62M
High today
$134.09
High today$134.09
Low today
$133.78
Low today$133.78
Open price
$134.92
Open price$134.92
Volume
9.00K
Volume9.00K
52 Week high
$157.29
52 Week high$157.29
52 Week low
$97.86
52 Week low$97.86

Stock Snapshot

As of today, Gilead Sciences(GILD) shares are valued at $134.00. The company's market cap stands at 167.59B, with a P/E ratio of 18.36 and a dividend yield of 2.4%.

As of 2026-05-13, Gilead Sciences(GILD) stock has fluctuated between $133.78 and $134.09. The current price stands at $134.00, placing the stock +0.2% above today's low and -0.1% off the high.

Gilead Sciences(GILD) shares are trading with a volume of 9K, against a daily average of 6.62M.

During the past year, Gilead Sciences(GILD) stock moved between $97.86 at its lowest and $157.29 at its peak.

During the past year, Gilead Sciences(GILD) stock moved between $97.86 at its lowest and $157.29 at its peak.

GILD News

Simply Wall St 3d
Did Gilead’s Mixed Q1, Buybacks and HIV Milestone Just Shift Gilead Sciences' Investment Narrative?

In early May 2026, Gilead Sciences reported first-quarter revenue of US$6.96 billion and net income of US$2.02 billion, while also completing a multi-year US$4....

Did Gilead’s Mixed Q1, Buybacks and HIV Milestone Just Shift Gilead Sciences' Investment Narrative?
TipRanks 5d
Gilead Sciences Balances Strong Growth With EPS Hit

Gilead Sciences ((GILD)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and pow...

Nasdaq 5d
Gilead Q1 2026 Earnings Call Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

Gilead Q1 2026 Earnings Call Transcript

Analyst ratings

75%

of 32 ratings
Buy
75%
Hold
21.9%
Sell
3.1%

More GILD News

Investor's Business Daily 6d
Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy

Gilead stock toppled late Thursday after the drugmaker issued a mixed guidance despite beating first-quarter sales expectations on the back of its HIV drugs Bik...

Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy
Simply Wall St 6d
A Look At Gilead Sciences Valuation After FDA Priority Review For New HIV Tablet

Gilead Sciences (GILD) recently drew attention after the FDA accepted its New Drug Application for a once daily bictegravir and lenacapavir HIV tablet. The appl...

A Look At Gilead Sciences Valuation After FDA Priority Review For New HIV Tablet
Benzinga 6d
Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings for its first quarter after the closing bell on Thursday, May 7. Analysts expect the Foster City, Cal...

Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.